[Detecting the activity of antibodies induced by recombinant TGFbeta1 vaccine].
OBJECTIVE
To measure the neutralization activity in vitro of the antibodies induced by recombinant TGFbeta1 vaccine and to evaluate the vaccine's anti-liver fibrosis activity.


METHODS
Balb/c mice were immunized with a fusion protein of the human TGFbeta1 epitope-inserted into a hepatitis B core antigen using a prokaryotic expression system. The antibody produced by the recombinant vaccine was determined using ELISA. The biological activity of the anti-TGFbeta1 antibody induced by the vaccine was measured by MTT using mink lung epithelial cell Mv-1-Lu as inhibiting cells. The fusion protein was used as a vaccine in a mice hepatic-fibrosis model.


RESULTS
A high titer of anti-TGFbeta1 antibody and a low of anti-HBc antibody were detected in the mice after the immunization. The serum antibodies induced combined with the fusion and antigenic peptide prevented the TGFbeta1 inhibiting activity in the Mv-1-Lu cell.


CONCLUSIONS
Recombinant fusion protein can be used as a cytokine vaccine to induce high titers of anti-TGFbeta1 antibodies. Our results show the potentiality of the fusion protein to be used as a vaccine for preventing liver fibrosis.
Guo
Yong-hong
YH
Department of Infectious Diseases, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Hao
Zhi-ming
ZM
Luo
Jin-yan
JY
Wang
Jun-hong
JH
D000818:Animals; D000906:Antibodies / Q000097:blood*; D002251:Carbon Tetrachloride; D002252:Carbon Tetrachloride Poisoning; D005260:Female; D006512:Hepatitis B Core Antigens / Q000096:biosynthesis / Q000276:immunology*; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D011387:Prokaryotic Cells / Q000378:metabolism; D011897:Random Allocation; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000276:immunology; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D000906:Antibodies; D006512:Hepatitis B Core Antigens; D011993:Recombinant Fusion Proteins; D053773:Transforming Growth Factor beta1; D014614:Vaccines, Synthetic; D002251:Carbon Tetrachloride